| Code | CSB-RA023986MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Denosumab-dssb, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates osteoclast differentiation, activation, and survival, playing a central role in bone remodeling and calcium metabolism. By binding to its receptor RANK on osteoclast precursors, TNFSF11 promotes bone resorption, making it a key mediator in conditions characterized by excessive bone loss. Dysregulation of the RANKL/RANK pathway is implicated in osteoporosis, bone metastases, rheumatoid arthritis, and multiple myeloma-related skeletal complications.
Denosumab-dssb is a fully humanized IgG2 monoclonal antibody that binds TNFSF11 with high affinity, preventing its interaction with RANK and thereby inhibiting osteoclast-mediated bone degradation. This biosimilar antibody serves as a valuable research tool for investigating bone metabolism, osteoclastogenesis, skeletal disease mechanisms, and RANKL signaling pathways in various experimental models. It enables researchers to explore therapeutic targets and mechanisms related to bone homeostasis and metabolic bone disorders.
There are currently no reviews for this product.